TET2 and acute myeloid leukemia: Abu-Shihab et al.’s study indicates that the most frequent co-occurring mutations in BRAF-mutated AML were TET2 (36%), ASXL1 (33%), NRAS (29%), KRAS (26%), and RUNX1 (19%) [12].